Prostate Cancer Utilities and Cost-Effectiveness Analysis

University of Chicago1 site in 1 country481 target enrollmentJanuary 2004

ConditionsProstate Cancer

Overview

Phase: N/A
Intervention: Not specified
Conditions: Prostate Cancer
Sponsor: University of Chicago
Enrollment: 481
Locations: 1
Primary Endpoint: Utility scores for treatment outcomes
Status: Completed
Last Updated: 8 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study is to help doctors and patients make better decisions about prostate cancer treatment. This research is being done because we do not know how patient preferences for health states related to prostate cancer affect the final treatment decision.

Detailed Description

The goal of this project is to incorporate patients' preferences into a previously developed prostate cancer treatment decision-model and to understand the implications for doing so for cost-effectiveness analysis. To do this, it is first necessary to obtain patient utility scores (i.e., patient preference weights). To do this we will perform a survey of patients visiting the urology clinic to undergo prostate biopsies to validate a method of utility assessment, and understand the patients' individual evaluations of treatment-related health studies. We will also ask patients questions relating to their anxiety levels concerning the possible diagnosis of prostate cancer.

Registry

clinicaltrials.gov

Start Date

January 2004

End Date

February 2013

Last Updated

8 years ago

Study Type

Observational

Sex

Male

Investigators

Sponsor

University of Chicago

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Patients undergoing prostate biopsy

Exclusion Criteria

•Women and children will be excluded, as prostate cancer occurs in men only
•Diagnosis of dementia

Outcomes

Primary Outcomes

Utility scores for treatment outcomes

Time Frame: 90 days after enrollment

Patient utility scores (i.e. patient preference weights) are calculated using survery data will determine which prostate cancer treatment would be most cost-effective for each subject. Patients will be contacted by phone and patient records will be reviewed 90 days after the survey has been completed to determine whether this data reflects actual treatment decisions.